Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
Key Training: Picking a Significant for Monetary Achievement- Experts who once backed 'shaken baby' science now fight to free imprisoned caregivers
- Sydney Sweeney's American Eagle campaign and Kendrick Lamar's Super Bowl performance were among the 10 biggest pop-culture moments of 2025
- Scientists have found an alarming environmental impact of vast data centers
- Advocacy groups react after Mattel introduces 1st Barbie doll with autism
- Unfathomable and Entertaining Legal disputes That Surprise everyone
- Most loved Specially prepared Espresso Mix: Which Meal Do You Adore the Most?
- Can a mammogram help identify heart disease?
- You finally got a doctor's appointment. Here's how to get the most out of it
